Effect of the peroxisome proliferator ciprofibrate on hepatic cyclooxygenase and phospholipase A 2 in rats
Toxicology, ISSN: 0300-483X, Vol: 126, Issue: 1, Page: 65-73
1998
- 11Citations
- 7Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Peroxisome proliferators, which include several hypolipidemic drugs, plasticizers and other chemicals, induce hepatic tumors in rodents. These chemicals alter the expression of enzymes involved in lipid metabolism, such as the cytochrome P450 4A family and peroxisomal β -oxidation enzymes. Previous studies have shown that the peroxisome proliferator ciprofibrate reduces eicosanoid concentrations in rat livers and primary hepatocyte cultures, yet the mechanism is still unclear. In this study we examined cyclooxygenases 1 and 2 (COX-1 and COX-2) and cytosolic phospholipase A 2 (cPLA 2 ) to determine whether the rate-limiting enzymes in the eicosanoid synthetic pathway are altered by ciprofibrate. Rats were fed 0.01% ciprofibrate for 3, 6, or 10 days. Western analysis revealed that COX-2 protein was induced by ciprofibrate (up to 13-fold at day 10), but that calcium-dependent (Ca-D) cPLA 2 protein was not different from controls. The enzyme activity of calcium-independent (Ca-I) cPLA 2 in ciprofibrate-treated rats was increased 2-fold, whereas Ca-D cPLA 2 and total COX activities were not affected. Using enzyme kinetics, we found that COX-1 ( K i =143 μ M) and Ca-I cPLA 2 ( K i =121 μ M) were competitively inhibited by ciprofibrate, but the inhibition was not physiologically significant. COX-2 and Ca-D cPLA 2 were not inhibited by ciprofibrate. These results show that ciprofibrate increases Ca-I cPLA 2 enzyme activity and COX-2 protein expression.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0300483X98000043; http://dx.doi.org/10.1016/s0300-483x(98)00004-3; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0032549039&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/9585093; http://linkinghub.elsevier.com/retrieve/pii/S0300483X98000043; http://api.elsevier.com/content/article/PII:S0300483X98000043?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0300483X98000043?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S0300483X98000043; http://dx.doi.org/10.1016/s0300-483x%2898%2900004-3; https://dx.doi.org/10.1016/s0300-483x%2898%2900004-3
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know